u/laila_almeida

Is that a VendorInvestigate result or are you quoting the vendor COA?

Not convinced. The evidence does not support that reading.

evidence-level statements required: in vitro, rodent, or human

This is correct. Weight variance is normal at maintenance.

Strongly agree. Phase 2 is investigational, not conclusive.

Regain on a taper is expected. 20% back over 26 weeks, which matches the discontinuation data. Planned for it.

Strongly agree. Escrow is non-negotiable for groups.

Not to be pedantic but secretagogue and thymosin are being used interchangeably and they are not interchangeable in real life.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

The confident tone is doing a lot of work that the evidence is not.

network selection matters, wrong chain is the expensive typo

Did you check confirmation speed on that chain?

phase 2 is not phase 3, smaller n and shorter trial

Disagree but this is the good kind of wrong — it is specific enough to be checked.

You have restated the marketing copy. What is the actual substance here.

Yeah, GL Biochem took 8 days and the material was flawless. Both of those things are true.

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

dropout handling matters, especially on GI-heavy populations

The confident tone is doing a lot of work that the evidence is not.

Small correction: the trial was 22 weeks, not 15. Does not change your point but people will quote it.